Hub Services Market Analysis: U.S. Pharmaceutical Patient Support Programs

Thesis

The hub services market is shifting from call-center-heavy patient support toward integrated access infrastructure: eBV/ePA, affordability management, specialty pharmacy coordination, and longitudinal patient data. For pharma buyers, the practical vendor question is no longer “who can staff a hub?” but “who can compress time-to-therapy while preserving manufacturer control over data, patient experience, and pharmacy routing.”

Scale still matters because large operators bring payer connectivity, EHR integrations, launch implementation capacity, and established quality systems. But the highest-risk buying mistakes now come from overbuying breadth without therapeutic fit, underweighting technology proof, or accepting black-box data terms that make future vendor switching difficult. Independent and specialist vendors can win when clinical depth, rare-disease intensity, or manufacturer data transparency matters more than distributor or PBM adjacency.

Implications

For launch teams: Treat hub selection as a launch-critical infrastructure decision, not a commodity outsourcing exercise. Require evidence on eBV/ePA performance, PA turnaround, enrollment-to-fill conversion, call center quality, data portability, and specialty pharmacy handoff control before weighting price.

For vendor shortlists: Use the product profile to set the lane. Broad specialty launches may need a full-stack operator with payer and pharmacy connectivity; rare disease, oncology, and cell/gene launches may justify a narrower specialist if it can prove clinical depth, high-touch operations, and clean data sharing.

For RFP diligence: Ask vendors to demonstrate live technology, not roadmap claims. Pressure-test how much of the workflow is electronic versus manual, who owns the patient record and phone/fax channels, what happens after a change of control, and how the vendor handles accumulator/maximizer, biosimilar, and CMS ePA complexity.

For competitive positioning: AI-native and hybrid hub models should be monitored as margin disruptors, but buyers should not mistake automation claims for operating maturity. The near-term winners are likely vendors that pair workflow automation with proven launch execution, therapeutic references, and manufacturer-accessible data.

Cluster Boundary

This page is the landscape page. It should answer “what is happening in the hub-services market?” and “which vendor archetypes exist?” It should not carry the detailed RFP, rate-card, or automation ROI work handled elsewhere:

• Hub services platforms ranks the core platform archetypes for shortlist design.
• Hub services buyer’s guide explains how to run the RFP.
• Hub pricing benchmarking normalizes bids.
• AI hub operations ROI tests automation economics.

Market Definition

Hub services are outsourced patient support programs operated by specialized third-party vendors on behalf of pharmaceutical manufacturers. They serve as the operational backbone connecting manufacturers, payers, pharmacies, and patients for specialty and high-cost therapies.

Sub-Segments

Sub-Segment	Description
Enrollment / Intake	Patient and prescriber onboarding, consent capture, program registration
Benefit Verification (eBV)	Electronic verification of insurance coverage, formulary status, cost-sharing
Prior Authorization (ePA)	Submission, tracking, and appeals management
Financial Assistance / Copay	Copay card administration, PAPs, bridge/free goods, manufacturer savings programs
Pharmacy Coordination	Specialty pharmacy routing, dispensing coordination, limited distribution drug management
Adherence / Nurse Support	Clinical nurse educators, adherence monitoring, refill management
Buy-and-Bill Reimbursement	Support for provider-administered biologics: medical benefit verification, claims support, J-code management

Scope Boundaries

In scope: Outsourced hub programs managed by third-party vendors; manufacturer-funded patient support; copay program administration fees; eBV/ePA technology platforms.

Out of scope: In-house pharma patient services teams; PBM-side formulary/UM; direct copay assistance spend ($23B+); specialty pharmacy dispensing revenue; clinical trial recruitment.

---

Market Size & Growth

Global Market

Year	Consensus Estimate	Source
2024	$3.2—3.4B	Grand View Research
2025E	$3.5—3.6B	Market.us
2026E	$3.9—4.0B	Extrapolated at 10% CAGR
2028E	$4.7—4.8B	Extrapolated at 10% CAGR

U.S. Operator-Fee Revenue

Year	Estimated U.S. Market	Growth
2023	~$1.2—1.3B	—
2024	~$1.4—1.8B (operator-fee revenue, 2024 US)	~9—10%
2025E	~$1.5—1.8B	~8—9%
2026E	~$1.6—1.9B	~8—9%
2028E	~$2.0—2.3B	~8—10%

Derived from Grand View Research U.S. data ($1.227B in 2023, 8.2% CAGR to 2030) and Market.us North America estimate of $1.7B in 2025.

Sizing caveat: public market estimates vary because some reports count outsourced hub operator fees while others blend in broader patient-support program management, affordability operations, technology, and adjacent pharmacy workflows. Treat the ranges above as directional and normalize any vendor-specific business case to the service scope actually being outsourced.

Sub-Segment Breakdown

Segment	Revenue Share (2024)	CAGR	Key Dynamics
Program Enrollment / Hub Ops	~31—33% (largest)	~6.4%	Core call-center enrollment; mature but volume growing with specialty launches
Reimbursement / Affordability	~20—22%	~11—12%	Fastest growing; copay card admin, PAP enrollment; driven by accumulator/maximizer complexity
Treatment Navigators (PA Mgmt)	~15—18%	~10.4%	Second-fastest growth segment
Clinical Educator / Adherence	~12—15%	~8%	Growing with cell/gene therapies
Specialty Pharmacy Coordination	~10—12%	~9%	SP routing, order management
Data / Analytics / Other	~8—10%	~12%	Emerging: AI-driven analytics, RWE support

Growth Drivers

1. Specialty drug pipeline (primary driver): Specialty spending reached $416.8B in U.S. in 2024 (51.7% of total Rx, +11.9% YoY). Specialty and rare-disease launches are the clearest demand driver because they create benefit-verification, PA, affordability, and pharmacy-routing work that traditional retail workflows do not solve.

2. GLP-1 and obesity-market access pressure: High-volume obesity and metabolic products create PA, affordability, fulfillment, and employer/payer routing complexity. Treat precise program economics as product-specific rather than universal hub benchmarks.

3. Prior authorization burden: Medicare Advantage insurers made nearly 53 million prior-authorization determinations in 2024, and CMS interoperability policy keeps pushing payer workflow toward standardized APIs. The 2026 CMS proposed drug-PA rule would extend that direction into prescription-drug prior authorization if finalized.

4. Biosimilar complexity: Record 18 new biosimilars approved in 2024; 40+ expected 2025—2027. Each launch creates competitive program layering (originator vs. biosimilar access programs).

5. Copay accumulator/maximizer dynamics: Manufacturers spent $23B on copay assistance in 2023, and Drug Channels reports that accumulator/maximizer designs affect roughly four in ten commercially insured lives. This adversarial dynamic drives demand for sophisticated hub-side financial navigation.

---

Competitive Tiers

Tier 1: Full-Stack / Largest

Offer hub services integrated with specialty pharmacy, drug distribution, broader commercialization, or massive provider/payer networks. Compete on breadth, infrastructure scale, and vertical integration.

Company	Ownership	Differentiators
EVERSANA	Private (Water Street / JLL; Waltz Health combination context)	Integrated commercialization, hub, affordability, specialty pharmacy, and pharma-to-payer connectivity post-Waltz
CareMetx-owned Lash/TheraCom	Private (CareMetx / General Atlantic, with Arsenal minority investment and Cencora preferred-partner context)	Long-tenured Lash hub operations and TheraCom free-goods pharmacy now under CareMetx; Cencora retains distribution adjacency but no longer owns the U.S. hub operator
McKesson / CoverMyMeds	Public (NYSE: MCK)	CoverMyMeds ePA network and McKesson distribution adjacency
Cardinal Health / Sonexus	Public (NYSE: CAH)	ConnectSource platform; AI-powered 24/7 patient chat; speech analytics
Valeris (PharmaCord + Mercalis)	PE (Permira; formed May 2025)	“Largest independent patient access company”; 2,900+ employees; 500+ clients
Optum	Public (NYSE: UNH)	PBM, specialty pharmacy, data, and payer adjacency; PBM affiliation limits manufacturer adoption.
IQVIA	Public (NYSE: IQV)	Real-world data, commercialization services, hub support, and pharmacovigilance

Tier 2: Independent Specialists

Focused primarily on hub services with deep expertise and strong tech platforms. Mostly PE-backed and actively building.

Company	Ownership	Differentiators
ConnectiveRx	PE-backed (Genstar Capital public-source ownership anchor)	Hub, adherence, affordability, awareness, and Careform noncommercial pharmacy
AssistRx	PE (WCAS since Feb 2024)	iAssist / CoAssist digital enrollment and therapy-initiation workflow; acquired AllazoHealth AI (Apr 2025)
Inizio Engage	PE (CD&R)	Trak360 platform; 96% first-call resolution; 35+ therapy areas; 25+ year rare disease heritage
CareTria	PE (Frazier since Feb 2025)	eBlu real-time BV/ePA (acquired Jul 2025); integrated SP + DTP + 3PL; rebranded Jan 2026
CareMetx	PE (General Atlantic-led; Vistria exited in 2025 secondary)	Digital hub, access workflow, and outcomes-contracting orientation
Phil	VC-backed	PHIL Direct digital access model and GLP-1 focus
Conduent	Public (NASDAQ: CNDT)	IntelliHealth and outsourced patient-support operations

Tier 3: Emerging / Niche

Newer entrants, technology-first disruptors, or narrow-focus specialists targeting specific therapeutic areas or operating paradigms.

Company	Key Positioning	Differentiators
Neon Health	AI-native hub; workforce automation-first	AI automation layer for specialty-access workflows
eMAX Health	Software licensing for hybrid/insourced hubs	ResponseRx; enables manufacturers to run hub tech in-house
Momentum Life Sciences	Clinical Nurse Educator specialist	One Voice adherence platform
ConnectMed360	Rare/oncology/orphan specialist	National non-commercial pharmacy (50-state); white-glove ultra-rare programs
Claritas Rx	Predictive analytics for hub optimization	Predictive discontinuation, abandonment, and PA-risk analytics
RareMed Solutions	Rare/orphan disease dedicated hub	RarePath Connect portal; ultra-orphan specialization

---

M&A Activity

Major Transactions (2020—2026)

Year	Target	Acquirer/Investor	Type
2020	ConnectiveRx investment / recapitalization	Genstar Capital public-source ownership anchor	PE recapitalization
2021	CareMetx	General Atlantic (majority) + Vistria (minority)	Growth equity recap
2021	Intouch Group	EVERSANA	Add-on (~$950M+)
2022	EVERSANA continuation fund	Water Street / JLL	$1.75B committed
2024 (Feb)	AssistRx	WCAS	PE acquisition (~$600M est.)
2024 (Sept)	PharmaCord	Permira	PE acquisition
2025 (Feb)	Knipper Health	Frazier Healthcare	PE acquisition
2025 (Mar—May)	Mercalis + PharmaCord —> Valeris	Permira (majority)	Platform merger
2025 (Apr)	AllazoHealth assets	AssistRx (WCAS)	Add-on
2025 (Jul)	eBlu Solutions	Knipper Health (Frazier)	Add-on
2025 (Aug)	EVERSANA + Waltz Health	Water Street/JLL + GV	Platform merger (~$6B combined)
2025 (Sept)	ConnectiveRx Pharmacy launch	ConnectiveRx	Organic vertical extension into DTP dispensing

PE Platforms Building in Hub Services

PE Firm	Platform	Strategy
Genstar Capital	ConnectiveRx	Hub + adherence + awareness; Careform + TMG acquisitions; added DTP pharmacy
Water Street / JLL	EVERSANA	Full-stack commercialization; 15+ acquisitions; Waltz Health merger (~$6B)
General Atlantic	CareMetx	Digital hub transformation, PX Technology + Human Care Systems add-ons, Arsenal minority investment, and 2026 Lash / TheraCom expansion
Frazier Healthcare	CareTria	Buy-and-build: Knipper + eBlu; therapy initiation platform
WCAS	AssistRx	EHR-native enrollment; AllazoHealth AI add-on
Permira	Valeris	PharmaCord + Mercalis merger; “largest independent patient access company”
CD&R	Inizio Engage	Ashfield + Huntsworth transformation; clinical/nurse hub model

Vertical Integration by Distributors

Big Three distributors have spent $16B+ on healthcare services/provider acquisitions since 2011:

• Cencora: Lash Group (2014), TheraCom ($250M, 2011), PharmaLex (1.28B EUR, 2022), OneOncology (~$5B, 2025)
• McKesson: CoverMyMeds ($1.1—1.4B, 2017), RxCrossroads ($735M, 2017), RxLightning, FastAuth
• Cardinal Health: Sonexus (2014), Specialty Networks ($1.2B, 2024), GI Alliance (~$2.8B, 2024)

Why PE Loves This Space

1. Recurring revenue with high switching costs: Multi-year contracts tied to specific drug brands make hub relationships sticky once launch operations are embedded.
2. Specialty drug tailwinds: Every new specialty or rare-disease approval drives incremental demand for benefit verification, PA support, affordability, and pharmacy routing.
3. Fragmented, consolidatable market: Dozens of sub-scale providers as of 2020—2022 — classic roll-up opportunity
4. Technology upgrade cycle driving margin expansion: Digital enrollment, ePA, and AI automation replacing headcount-heavy models
5. Data network effects: Hub platforms sit on rich patient adherence, payer coverage, prescriber behavior, and dispensing data — increasingly monetizable

Deal Multiples

No hub-specific EBITDA multiples publicly disclosed. Comparable healthcare services technology transactions: 7x—15x EBITDA and 2x—6x revenue. Platform transactions with recurring revenue and tech differentiation command 12x—16x EBITDA.

---

Technology Differentiation

eBV/ePA Capabilities

Platform	Network Scale	Key Capability
CoverMyMeds (McKesson)	Large EHR, pharmacy, and provider network	ePA determination and status workflow
Surescripts Touchless PA	Prescriber and medication coverage network	Touchless PA workflow
Eversana ACTICS	Hub-connected payer-access platform	Real-time eBV + ePA integrated with hub workflow
Agadia PromptPA	Health-plan/PBM direct-connection model	Direct payer connections for specialty medications

Eversana eBV claim assessment: Treat ACTICS coverage metrics as vendor-disclosed platform claims unless independently audited. They are not directly comparable to broad ePA network-share claims or older algorithm-based ePA benchmarks.

AI / Automation

Key applications:

• Enrollment automation: Digital enrollment reduces fax, portal, and manual follow-up work.
• PA decisioning: Payer-side tools combine clinical criteria, workflow routing, and regulatory reporting.
• Adherence prediction: Analytics vendors flag abandonment, discontinuation, and denial risk earlier in the patient journey.
• Call center NLP: Intent recognition, auto-STT, sentiment analysis, OCR for faxed forms. Conduent IntelliHealth automates 50% of routine agent tasks.
• AI-powered PSP outcomes: Treat vendor-published PSP outcome claims as diligence inputs until independently audited.

Digital Hub Models

Model	Description	Examples
Full-Service Digital Hub	End-to-end: BI/BV, ePA, copay, adherence, nursing, analytics	CareMetx / Lash-TheraCom, EVERSANA
Hub-Lite	Intake + light BV + routing to SP	Smaller programs, post-LOE brands
DTP / Digital-First	Consumer-facing app: Rx + telehealth + fulfillment	Phil (PHIL Direct), AssistRx Gateway
Hybrid / Dedicated	Manufacturer insources tech; outsources staffing	eMAX Health software licensing model

CMS ePA Mandate (January 2027)

FHIR-based APIs for payer PA standardized across all Medicare/Medicaid payers. Hub vendors with early FHIR compliance (CoverMyMeds, Surescripts ecosystem) hold integration advantage. EHR-embedded workflows are becoming table stakes.

---

Win/Loss Dynamics

Vendor Selection Criteria

Based on 2024 CareMetx Patient Services Report (survey of market access leaders):

Priority	Criterion	Est. Weight
1	Comprehensive suite of patient services solutions	~25%
2	Strong understanding of patient journey alignment	~20%
3	Flexible/customizable service offering	~15%
4	Demonstrated performance metrics / evidence of results	~15%
5	Technology — enrollment automation and EHR integration	~15%
—	Therapeutic area expertise, data transparency, cost	~10% combined

Switching Drivers

Reason	Frequency	Details
Poor data transparency / “black box”	Most common	Hubs providing quarterly summaries while keeping insights locked; driving pharma to insource technology
Technology inadequacy	Increasing	Failure to offer digital enrollment, EHR integration, real-time eBV/ePA
Underperformance on speed-to-therapy	Common	Missing time-to-first-fill KPIs triggers formal review
Data ownership disputes	Emerging	Manufacturer demands for data portability that incumbent resists
M&A / Strategic realignment	Periodic	Consolidation activity forces program re-evaluation

Switching inhibitors: Revenue risk during transition estimated at 5—10% of brand revenue. New hub onboarding requires 90—180+ days for complex programs. Manufacturers spend >$5B annually on patient access programs — switching represents significant operational risk.

Contract Structure

• Initial term: 3 years (standard full-service hub)
• Renewals: 1-year by mutual agreement; some evergreen
• Pricing models: Transactional (per-BV, per-PA, per-call), FTE-based, Hybrid (FTE base + transactional), PPPM ($75—200/patient/month for adherence), Value/outcomes-based (tied to fill rates, adherence)
• Hub-lite/transactional: 1—2 year terms with easier exit

Decision-Makers

Market access leads serve as primary decision-maker ~1/3 of the time, with cross-functional influence from commercial ops, patient services, brand/marketing, procurement, and medical affairs. External consultants (Blue Fin Group, Protean, TwoLabs) frequently engaged for vendor selection.

---

Market-Level Buyer Signals

Hub-specific public benchmarks are thin and often vendor-reported. Use market signals to shape diligence, then require program-level proof in the RFP.

Signal	What it means for buyers	Where to go next
PA burden keeps rising	BV/PA workflow, payer-rule intelligence, status visibility, and appeal support are now core infrastructure, not back-office extras.	Hub Services Buyer’s Guide
Accumulator / maximizer complexity is mainstream	Affordability operations must be integrated with hub data, copay administration, PAP screening, and gross-to-net controls.	Copay accumulator / maximizer and Hub Pricing Benchmarking
Cencora/Lash moved to CareMetx	Incumbent Lash/TheraCom buyers should treat CareMetx as the operating counterparty and diligence transition risk.	CareMetx and Hub Services Platforms
Valeris and CareTria show PE platform-building	Independent patient-access platforms are being assembled through mergers and add-ons, so change-of-control rights matter.	Hub Services Buyer’s Guide
AI-native workflow vendors are credible but uneven	Automation can reduce repeatable payer-contact work, but it does not replace clinical judgment or high-touch rare-disease casework.	AI Hub Operations ROI

---

Outlook

Growth Catalysts (2025—2028)

1. Specialty drug pipeline acceleration: 80+ rare disease drugs through 2027; cell/gene therapies ($3.5M+ per dose) each requiring dedicated hub infrastructure
2. GLP-1 access expansion: CMS Medicare Bridge (July 2026); expanding indications (CV, renal, sleep apnea, Alzheimer’s) multiplying program scope
3. CMS ePA mandate (January 2027): FHIR-based standardized PA APIs reshape hub tech requirements; early compliance = competitive advantage
4. AI-driven margin expansion: automation may reduce enrollment, PA, and call-center labor intensity, but buyer diligence should separate vendor claims from audited program outcomes
5. Biosimilar program layering: 40+ launches creating competitive complexity and duplicate hub demand

Key Risks

1. In-sourcing by large pharma: Manufacturers “reclaiming control over patient experience” by insourcing hub technology while retaining outsourced staffing — compressing traditional hub vendor scope
2. AI disruption of call center model: AI-native automation could compress traditional FTE-heavy workflows, but most public claims remain vendor-reported and need proof in comparable programs.
3. Copay accumulator/maximizer expansion: PBMs capture ~$6.5B of manufacturer copay funds annually. If accumulators expand further, the $23B copay spending demand driver could face structural headwinds.
4. Regulatory risk: Transparency mandates, potential federal accumulator regulation, and state-level copay reform could alter the financial assistance landscape
5. PE concentration risk: Aggressive roll-ups could reduce competition/innovation. If platforms prioritize margin extraction over quality, buyers may accelerate insourcing.
6. Cybersecurity: Cencora/Lash Group 2024 breach (1.43M individuals, $40M settlement) highlights PHI risk for hub operators

Predictions

• U.S. operator-fee revenue should continue growing from the 2023 Grand View Research base
• AI-native entrants pressure labor-heavy incumbents where workflows are repeatable and integration risk is low
• 2—3 additional major PE transactions through 2027 among independent hub and patient-access platforms
• Distributor integration is uneven: McKesson and Cardinal Health continue building patient services around distribution adjacency, while Cencora shifted its U.S. Lash/TheraCom hub operations to CareMetx and retained preferred-partner context rather than direct ownership
• Hybrid hub models become standard: Binary outsourced vs. insourced dissolves — manufacturers own tech, outsource staffing/clinical
• Data monetization emerges: Hub operators commercialize analytics products, RWE packages, and predictive tools from longitudinal patient journey data

---

Cross-References

• Hub Services category page
• Hub Services Overview (concept)
• Hub Services Platforms
• Hub Services Buyer’s Guide
• Hub Pricing Benchmarking
• AI Hub Operations ROI

---

Analysis compiled April 2026. All market size estimates based on publicly available research reports and should be treated as directional. Deal values marked as estimated or undisclosed reflect best available information from press releases, industry sources, and financial media. Hub-specific benchmarks (program costs, call center metrics) have limited public disclosure; figures synthesized from contextual data and adjacent market information.